Report from EGM 12 June 2019
Bio-Works publishes the report from its Extraordinary General Meeting held on 12 June 2019.
Bio-Works present at Småbolagsdagen
Bio-Works participates in Småbolagsdagen, presenting its business and growth strategy to Swedish investors and analysts.
Quarterly report Q1 2019
Bio-Works releases its Q1 2019 quarterly report covering financial performance and key operational developments.
mAb Purification – an overview of the essentials
Five of the top ten best selling drugs in 2017 were mAbs and the global [...]
Presentation at Vator Securities Unicorn Summit
Mats Johnson, CEO of Bio-Works, will be presenting at the Vator Securities Unicorn Summit on Thursday [...]
Optimizing mAb purification with next generation protein A resin
The market for monoclonal antibodies (mAbs) is constantly growing as mAb therapies are generally considered [...]
Some general tips on protein purification strategy
Can you generalize about something as broad as protein purification strategy? Surely it depends on [...]
Investment presentation at BioStock
Bio-Works presents investment case at BioStock, highlighting its technology and growth opportunities in Nordic life sciences.
Bio-Works is now ISO 9001:2015 certified
Bio-Works achieves ISO 9001:2015 certification, demonstrating its commitment to quality management and regulatory compliance.
Bokslutskommuniké Januari – december 2018
Bio-Works publicerar sin bokslutskommuniké för januari–december 2018 med finansiella resultat och viktiga händelser.
